News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 13, 2024

Foreseeable Biosimilar Trends

The expert panel discuss future trends in the biosimilar space.

Episodes in this series

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

A panel of 4 experts on biosimilars

EP. 7 Private Label Biosimilars

EP. 8 Biosimilars in the Commercial Sector

EP. 8 Biosimilars in the Commercial Sector

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 11 Unmet Needs and Future Initiatives

EP. 11 Unmet Needs and Future Initiatives

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 13 Foreseeable Biosimilar Trends

EP. 13 Foreseeable Biosimilar Trends

EP. 14 Legislative Support for Biosimilars

EP. 14 Legislative Support for Biosimilars

EP. 15 Key Takeaways for Biosimilar Utilization

EP. 15 Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

What’s next for biosimilars in the US? What are the anticipated trends in biosimilar development and approval over the next few years?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

2 experts are featured in this video

Inside the Be-Well Trials: Design, Population, and Patient Selection

ByRaymond Chung, MD,Douglas Dieterich, MD

September 10th 2026

Counseling Vitiligo Patients on Time to Repigmentation

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Trending on AJMC

Counseling Vitiligo Patients on Time to Repigmentation

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

5 August FDA Approvals Marked by Novelty, Pushback

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD